"We are pleased to have safely implanted the first patient in China with the TaurusTrio™ TAVR System," said Dr. Yi Zhang, Chief Executive Officer of Peija Medical. "The trial reinforces our goals of improving care in the field of cardiology and expanding TAVR systems within China. We are looking forward to our continued partnership with American company, JenaValve and presenting further data from the clinical trial at a future date."